Company Description
scPharmaceuticals Inc., a pharmaceutical company, focuses on developing and commercializing products to optimize the delivery of infused therapies and patient care.
The company’s lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for the treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX.
Its product pipeline also includes SCP-111 (furosemide injection), an investigational pH neutral aqueous furosemide formulation that is being developed for subcutaneous administration outside of the hospital setting, including patient self-administration in the home; and SCP-111 Autoinjector, an investigational single-entity and drug-device combination product candidate consisting of a prefilled syringe containing SCP-111 preloaded into a mechanical autoinjector.
The company was incorporated in 2013 and is headquartered in Burlington, Massachusetts.
| Country | United States |
| Founded | 2013 |
| IPO Date | Nov 17, 2017 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 164 |
| CEO | John Tucker |
Contact Details
Address: 25 Mall Road, Suite 203 Burlington, Massachusetts 01803 United States | |
| Phone | 617 517 0730 |
| Website | scpharmaceuticals.com |
Stock Details
| Ticker Symbol | SCPH |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001604950 |
| CUSIP Number | 810648105 |
| ISIN Number | US8106481059 |
| Employer ID | 46-5184075 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| John H. Tucker | President, Chief Executive Officer, Principal Executive Officer and Director |
| Rachael Nokes | Chief Financial Officer |
| Michael D. Hassman | Senior Vice President of Technical Operations |
| Katherine Taudvin | Vice President of Corporate Affairs and Human Resources |
| Dr. John Mohr Pharm.D. | Senior Vice President of Clinical Development and Medical Affairs |
| Steve C. Parsons | Senior Vice President of Commercial |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 7, 2025 | 10-Q | Quarterly Report |
| Aug 7, 2025 | 8-K | Current Report |
| Jul 21, 2025 | SCHEDULE 13G/A | Filing |
| Jun 9, 2025 | 8-K | Current Report |
| May 14, 2025 | 10-Q | Quarterly Report |
| May 14, 2025 | 8-K | Current Report |
| Apr 28, 2025 | SCHEDULE 13G/A | Filing |
| Apr 21, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 21, 2025 | DEF 14A | Other definitive proxy statements |
| Mar 19, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |